The underlying argument was to preserve cortical function in patients with a high risk of bilateral PCC having a low risk of metastatic disease (RET and VHL carriers), whereas those with a low risk of bilateral PPC but with risk factors for metastases (including SDHB and large tumor size) could benefit from an open approach to maximize probability of radical resection. This evidence concerns the gene SDHB and metastatic neoplasm.